Executive summary

Published in the Red Journal, this retrospective analysis by MD Anderson group reviewed 203 patients treated with protons or IMRT to 66-74 Gy(RBE) in 33-37 fractions with concurrent carboplatin/paclitaxel.

By analyzing the 46 experienced grade ≥2 radiation pneumonitis at a median 3.7 months, this study found that the effective dose (Deff) with n=0.5 (corresponding to root mean squared dose) is a better predictor of RP than MLD. Differences between Deff and MLD indicate that delivering higher doses to smaller lung volumes (vs. lower doses to larger volumes) increases RP risk.

Top cancer treatments